Document Classification

Section Type: RESULTS

Text: In addition, the results for the all therapeutic effects showed identical trends to the results obtained in the original analysis, including the statistically similar effects of ETV and ETV maleate treatment-induced decreases in mean HBV DNA level at weeks 12, 24, and 48 (ETV : by 4. 28, 5. 00, and 5. 53 log10 IU/ml vs. ETV maleate : by 4. 46, 4. 99, and 5. 51 log10 IU/ml, respectively ; all vs. baseline P more than 0. 05), achievement of undetectable levels of serum HBV DNA (less than 20 IU/ml) at week 48 (ETV : 38. 18 % vs. ETV maleate : 35. 19 % ; P more than 0. 05), HBeAg loss rates at week 48 (ETV : 10. 91 % vs. ETV maleate : 12. 96 % ; P more than 0. 05), HBeAg seroconversion rates at week 48 (ETV : 7. 77 % vs. ETV maleate : 10. 38 % ; P more than 0. 05), normalization of alanine aminotransferase at week 48 (ETV : 75. 47 % vs. ETV maleate : 82. 86 % ; P more than 0. 05), and overall incidence of AE (ETV : 18. 02 % vs. ETV maleate : 17. 43 % ; P more than 0. 05).